Table 1.
Patient information. TMP/SMX, trimethoprim/sulfamethoxazole; AMP/SUL, ampicillin/sulbactam; AMO/CLU, amoxicillin/clavulanate.
| Group | Study ID | Gender | Age | SNOT-20 | Antimicrobial treatment |
|
|---|---|---|---|---|---|---|
| Preoperative | Perioperative | |||||
| CRS | CRS-001* | M | 54 | 2.75 | None† | Cefazolin |
| CRS | CRS-002 | M | 54 | 2.35 | TMP/SMX | Vancomycin |
| CRS | CRS-003* | M | 48 | 2.65 | None | AMP/SUL |
| CRS | CRS-004 | M | 33 | 3.60 | None | Cefazolin |
| CRS | CRS-005* | M | 56 | 2.65 | Clarithromycin | Cefazolin |
| CRS | CRS-006 | F | 41 | 1.85 | None | Cefazolin |
| CRS | CRS-007 | M | 60 | 3.00 | Clarithromycin | Levofloxacin |
| CRS | CRS-008 | M | 53 | 1.55 | Ciprofloxacin | Cefazolin |
| CRS | CRS-009 | F | 46 | 2.35 | AMO/CLU | Cefazolin |
| Control | CRS-010 | M | 62 | 0.90 | Levofloxacin | Ceftriaxone |
| CRS | CRS-011 | M | 42 | 3.35 | AMO/CLU | Clindamycin |
| Control | CRS-012* | M | 43 | 0.15 | None | Clindamycin |
| Control | CRS-013 | F | 73 | 1.70 | None | Cefazolin |
| Control | CRS-014 | M | 41 | 2.60 | None | Clindamycin |
| Control | CRS-015* | M | 39 | 0.00 | None | Clindamycin |
| Control | CRS-016* | F | 37 | 2.25 | None | Cefazolin |
| Control | CRS-017 | F | 46 | 0.10 | None | Clindamycin |
| Control | CRS-018 | M | 46 | 2.15 | None | Clindamycin |
| Control | CRS-019 | F | 31 | 0.50 | None | Clindamycin |
| Control | CRS-020 | F | 18 | 0.30 | None | Clindamycin |
*
Microbiota profiling was not performed for these subject samples because of insufficient 16S rRNA amplicon.
†
No antibiotics administered.